Desloratadine on G-CSF derivatives induced bone pai

Phase 3

Recruiting

• Conditions: Cancer.; Encounter for antineoplastic chemotherapy; Z51.11

• Registration Number: IRCT20200220046560N2
• Lead Sponsor: Oroumia University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 11 January 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 88

Inclusion Criteria

Age older than 18 years old
Indication for chemotherapy
Receive 1 to 3 course of chemotherapy before entry to study
Occurrence bone pain with VAS score= 4 within 8 days of G-CSF derivatives injection

Exclusion Criteria

History of allergy to desloratadine or loratadine
Chronic use of opioid (addiction)
Chronic use of antihistamine ( more than 2 weeks during the previous month ) before entrance to study
metastasis to bone
Diagnosed Osteomalacia
Known rheumatological disease associated with chronic bone pain
Known hyperparathyroidism
History of Allergy to naproxen
Chronic kidney disease with GFR < 15 ml/min

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pain. Timepoint: Daily for the first 8 days of each chemotherapy course. Method of measurement: Brief pain questionnaire, Visual Analogue Scale.

Secondary Outcome Measures

Name	Time	Method
Quality of life. Timepoint: Beginning and at the end of therapy. Method of measurement: The European Organization for Research and Treatment of Cancer QOL Core Questionnaire 30.